Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › SYNCHRONIZE-1

SYNCHRONIZE-1

Survodutide · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Survodutide
Population
obesity
Official title
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
Sponsor
Boehringer Ingelheim
Phase
3
Registry status
completed · 2023-11 → 2025-12
Participants
726
Duration
76 weeks
Registry
NCT06066515

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
survodutide 3.6 mgobesity76241−15.3 % vs −3.2 %
Δ −12.1 pp
−12.2 % vs −5.4 %
Δ −6.8 pp
−0.2 vs +0.023.7 vs 5.435.3 vs 40.161.0 vs 17.440.7 vs 6.28.3 vs 6.2−6.7 vs −5.9verified
survodutide 6.0 mgobesity76242−16.6 % vs −3.2 %
Δ −13.4 pp
−13.0 % vs −5.4 %
Δ −7.6 pp
−0.2 vs +0.024.8 vs 5.434.3 vs 40.164.9 vs 17.444.6 vs 6.28.3 vs 6.2−5.4 vs −5.9verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (18)
  • survodutide 3.6 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Figure 1B
    −15.3% with 3.6 mg of survodutide, –16.6% with 6.0 mg of survodutide, and –3.2% with placebo
  • survodutide 3.6 mg · weight_tp · Table 1
    Mean change in body weight (95% CI) — % –12.2 (–13.6 to –10.8) –13.0 (–14.4 to –11.6) –5.4 (–6.9 to –4.0)
  • survodutide 3.6 mg · ae_dc · Table 3
    Adverse event leading to discontinuation of survodutide or placebo 57 (23.7) 60 (24.8) 13 (5.4)
  • survodutide 3.6 mg · nausea · Table 3
    Nausea 147 (61.0) 157 (64.9) 42 (17.4)
  • survodutide 3.6 mg · vomiting · Table 3
    Vomiting 98 (40.7) 108 (44.6) 15 (6.2)
  • survodutide 3.6 mg · sae · Table 3
    Any serious adverse event 20 (8.3) 20 (8.3) 15 (6.2)
  • survodutide 3.6 mg · hba1c · Table 2
    Mean change in glycated hemoglobin level (95% CI) — percentage points –0.2 (–0.2 to –0.1) –0.2 (–0.2 to –0.1) 0.0 (–0.1 to 0.1)
  • survodutide 3.6 mg · sbp · Table 1
    Mean change in systolic blood pressure — mm Hg –6.7 –5.4 –5.9
  • survodutide 3.6 mg · disc_any · Results, participants paragraph
    63.4% were still receiving survodutide or placebo at 76 weeks (64.7%, 65.7%, and 59.9%, respectively)
  • survodutide 6.0 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Figure 1B
    −15.3% with 3.6 mg of survodutide, –16.6% with 6.0 mg of survodutide, and –3.2% with placebo
  • survodutide 6.0 mg · weight_tp · Table 1
    Mean change in body weight (95% CI) — % –12.2 (–13.6 to –10.8) –13.0 (–14.4 to –11.6) –5.4 (–6.9 to –4.0)
  • survodutide 6.0 mg · ae_dc · Table 3
    Adverse event leading to discontinuation of survodutide or placebo 57 (23.7) 60 (24.8) 13 (5.4)
  • survodutide 6.0 mg · nausea · Table 3
    Nausea 147 (61.0) 157 (64.9) 42 (17.4)
  • survodutide 6.0 mg · vomiting · Table 3
    Vomiting 98 (40.7) 108 (44.6) 15 (6.2)
  • survodutide 6.0 mg · sae · Table 3
    Any serious adverse event 20 (8.3) 20 (8.3) 15 (6.2)
  • survodutide 6.0 mg · hba1c · Table 2
    Mean change in glycated hemoglobin level (95% CI) — percentage points –0.2 (–0.2 to –0.1) –0.2 (–0.2 to –0.1) 0.0 (–0.1 to 0.1)
  • survodutide 6.0 mg · sbp · Table 1
    Mean change in systolic blood pressure — mm Hg –6.7 –5.4 –5.9
  • survodutide 6.0 mg · disc_any · Results, participants paragraph
    63.4% were still receiving survodutide or placebo at 76 weeks (64.7%, 65.7%, and 59.9%, respectively)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: SYNCHRONIZE-1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/synchronize-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.